Naganawa Hirokazu, Ito Akira, Saiki Shinrou, Nishi Daisuke, Takamatsu Shinichi, Ito Yoshihisa, Suzuki Takeshi
Department of Cardiology, Toyokawa City Hospital, Toyokawa, Aichi, Japan.
Cardiol Res Pract. 2023 Apr 20;2023:4594818. doi: 10.1155/2023/4594818. eCollection 2023.
Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS.
In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year.
Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (=0.73).
DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.
使用药物洗脱支架（DES）进行经皮冠状动脉介入治疗是急性冠状动脉综合征（ACS）的常见治疗选择。然而，与支架相关的并发症，如双联抗血小板治疗相关的出血、支架内再狭窄、支架血栓形成和新生动脉粥样硬化，仍然存在。药物涂层球囊（DCB）有望减少与支架相关的并发症。本研究旨在评估DCB治疗的疗效，并将其与ACS患者的DES治疗疗效进行比较。
在这项单中心、回顾性、观察性研究中，我们检查了2014年7月至2020年11月期间接受DCB或DES治疗的所有ACS患者。排除左主干病变患者。主要结局是1年时的主要不良心血管事件（MACE：心源性死亡、心肌梗死和靶病变血运重建）复合终点。
372例患者接受了DES治疗，83例患者接受了DCB治疗。DCB组有10例（12.0%）患者发生MACE，DES组有50例（13.4%）患者发生MACE（P=0.73）。
DCB是ACS患者一种有价值且有效的治疗方法。此外，DCB可能成为ACS患者DES的替代治疗方法。
